2 results
Approved WMOCompleted
Primary Safety Objective * Proportion of patients who complete 24 weeks of combination treatment on pirfenidone at a dose of 1602*2403 mg/d and nintedanib at a dose of 200*300 mg/d Secondary Safety Objective * Proportion of patients who discontinue…
Approved WMOCompleted
Primary objective is to quantitatively assess differences in in vivo neuroinflammation in patients before and after coronary artery bypass grafting (CABG) surgery. Secondary objective is to study whether diffferences in in vivo neuroinflammation are…